Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
Items 301–400 of 1,000
Kumar, S. K., Moreau, P., Hari, P., Mateos, M., Ludwig, H., Shustik, C., Masszi, T., Spencer, A. G., Hájek, R., Romeril, K. R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14733 · Cited by 59
Self-citationUpdate on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 61
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E., & Agarwal, A. (2021) · Oncotarget · doi:10.18632/oncotarget.27973 · Cited by 66
Zangari, M., Tricot, G. J. K., Polavaram, L., Zhan, F., Finlayson, A., Knight, R., Fu, T., Weber, D., Dimopoulos, M. A., Niesvizky, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0169 · Cited by 58
“Thromboembolic complications were later observed with the introduction of lenalidomide and pomalidomide used in combination with dexamethasone or standard chemotherapy.(8,9) In patients with relapsed myeloma treated with lenalidomide and high-dose dexamethasone, the incidence of VTE ranges widely in different centers…”
Self-citationChemotherapy-induced peripheral neuropathies in hematological malignancies
Jongen, J. L. M., Broijl, A., & Sonneveld, P. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1632-x · Cited by 63
“In phase I, II and III clinical trials, lenalidomide neurotoxicity concerned mainly grade 1–2 peripheral neuropathy [41].”
BackgroundŠpıčka, I., Ocio, E. M., Oakervee, H. E., Greil, R., Banh, R. H., Huang, S., D’Rozario, J. M., Dimopoulos, M. A., Martínez, S., Extremera, S., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03739-2 · Cited by 62
Self-citationTreatment of relapsed multiple myeloma: Evidence-based recommendations
Durer, C., Durer, S., Lee, S., Chakraborty, R., Malik, M. N., Rafae, A., Zar, M. A., Kamal, A., Rosko, N., Samaras, C. J., et al. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100616 · Cited by 59
Kropff, M. H., Baylon, H. G., Hillengaß, J., Robak, T., Hájek, R., Liebisch, P., Goranova-Marinova, V. S., Hulin, C., Bladé, J., Caravita, T., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044271 · Cited by 61
“7 months in the MM-009 and MM-010 trials.(9,10) One possible reason for the discrepancy may lie in the types of patients enrolled.”
BackgroundSelf-citationAcaster, S., Gaugris, S., Velikova, G., Yong, K., & Lloyd, A. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1548-y · Cited by 56
Hideshima, T., Cottini, F., Nozawa, Y., Seo, H., Ohguchi, H., Samur, M., Cirstea, D. D., Mimura, N., Iwasawa, Y., Richardson, P. G. G., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738500 · Cited by 60
Schey, S. A., Morgan, G. J., Ramasamy, K., Hazel, B., Ladon, D., Corderoy, S., Jenner, M., Phekoo, K., Boyd, K., & Davies, F. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08250.x · Cited by 57
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Franqui-Machin, R., Wendlandt, E. B., Janz, S., Zhan, F., & Tricot, G. J. K. (2015) · Oncotarget · doi:10.18632/oncotarget.5800 · Cited by 63
“These include the antineoplastic alkylating agents, cyclophosphamide, busulfan, BCNU and melphalan, the pleiotropic immunomodulator, thalidomide, and its derivatives, corticosteroids, including dexamethasone, microtubule-targeting agents, such as paclitaxel and the vinca alkaloids, and the proteasome inhibitors, borte…”
BackgroundNijhof, I. S., Franssen, L. E., Levin, M.-D., Bos, G. M. J., Broijl, A., Klein, S. K., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., et al. (2016) · Blood · doi:10.1182/blood-2016-07-729236 · Cited by 55
How I manage the toxicities of myeloma drugs
Delforge, M., & Ludwig, H. (2017) · Blood · doi:10.1182/blood-2017-01-725705 · Cited by 58
Fenk, R. R., Liese, V., Neubauer, F., Bruns, I., Kondakci, M., Balleisen, S., Saure, C., Schröder, T., Haas, R. R., & Kobbe, G. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.575967 · Cited by 56
“The therapeutic efficacy of incorporating compounds such as thalidomide [7], bortezomib [8], or lenalidomide [9,10] into HDT-based regimens is currently being evaluated in several clinical trials [11–13].”
BackgroundDrappatz, J., Wong, E. T., Schiff, D., Kesari, S., Batchelor, T. T., Doherty, L. M., LaFrankie, D. C., Ramakrishna, N. R., Weiss, S. E., Smith, S. T., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.03.046 · Cited by 54
Korthals, M., Sehnke, N., Kronenwett, R., Bruns, I., Mau, J., Zohren, F., Haas, R. R., Kobbe, G., & Fenk, R. R. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.002 · Cited by 55
“Because drugs such as thalidomide [6], bortezomib [7], or lenalidomide [8] are quite effective and associated with a considerably higher proportion of patients with very good partial remission (vgPR) or complete remission (CR), the detection of minimal residual disease (MRD) in patients withMMcould be of particular re…”
BackgroundAl‐Farsi, K. (2013) · Oman Medical Journal · doi:10.5001/omj.2013.02 · Cited by 61
Update of thrombosis in multiple myeloma
Leebeek, F. W. G. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30103-7 · Cited by 53
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A. A., Cohen, A. D., Devine, S. M., Djulbegović, B., Faber, E. A., Gasparetto, C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0095 · Cited by 68
Stefano, V. D., Larocca, A., Carpenedo, M., Cavo, M., Raimondo, F. D., Falanga, A., Offidani, M., Petrucci, M. T., Ruggeri, M., Santi, R. M., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280893 · Cited by 61
Yang, B., Yu, R.-L., Chi, X.-H., & Lu, X.-C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064354 · Cited by 53
“boprophylaxis is clearly indicated for patients being treated with lenalidomide to ameliorate the risk of deep vein thrombosis and other thrombolytic events [24,26,30].”
BackgroundPalumbo, A. P., Mateos, M., Bringhen, S., & Miguel, J. F. S. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.03.005 · Cited by 54
“Lenalidomide:Neutropenia and thrombocytopenia are major dose-limiting toxicities of lenalidomide therapy; 11,12,19 respective grade 3/4 rates of around 12–20% and 7–8% have been reported in combination with dexamethasone in newly diagnosed patients,(20) although in relapsed/refractory patients, rates of up to 41% and…”
BackgroundSelf-citationBerenson, J. R., Yellin, O., Bessudo, A., Boccia, R. V., Noga, S. J., Gravenor, D. S., Patel‐Donnelly, D., Siegel, R. S., Kewalramani, T., Gorak, E. J., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12129 · Cited by 55
“…of recently approved agents, such as bortezomib, lenalidomide and thalidomide, in the treatment of MM has also improved response rates and overall survival (OS) (Richardson et al, 2005; Brinker et al, 2006; Dimopoulos et al, 2007; Gay et al, 2010; Mateos et al, 2010; Roussel et al, 2010).”
BackgroundVascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies
Medinger, M., Fischer, N., & Tzankov, A. (2010) · Journal of Oncology · doi:10.1155/2010/729725 · Cited by 52
“In 2 phase III trials, lenalidomide in combination with dexamethasone resulted in remarkable response rates and significantly less toxicity than thalidomide [92, 93], and increased the response rate from 22.”
Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma
Bergsagel, P. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.199 · Cited by 53
Díaz, T., Rodríguez, V., Lozano, E., Mena, M.-P., Calderón, M., Rosiñol, L., Martínez, A., Tovar, N., Pérez‐Galán, P., Bladé, J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.164632 · Cited by 54
CD48 as a novel molecular target for antibody therapy in multiple myeloma
Hosen, N., Ichihara, H., Mugitani, A., Aoyama, Y., Fukuda, Y., Kishida, S., Matsuoka, Y., Nakajima, H., Kawakami, M., Yamagami, T., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08941.x · Cited by 56
“Thalidomide (Singhal et al, 1999), bortezomib (Richardson et al, 2003) and lenalidomide (Dimopoulos et al, 2007) have all emerged as very effective drugs for MM.”
BackgroundKaya, H., Peressini, B., Jawed, I., Martincic, D., Elaimy, A. L., Lamoreaux, W. T., Fairbanks, R. K., Weeks, K. A., & Lee, C. M. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0971-z · Cited by 52
Jakubowiak, A. J., Campioni, M., Benedict, Á., Houisse, I., Tichy, E., Giannopoulou, A., Aggarwal, S. K., Barber, B., & Panjabi, S. S. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1194278 · Cited by 52
The molecular mechanism of thalidomide analogs in hematologic malignancies
Lindner, S., & Krönke, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1450-z · Cited by 53
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States
Carlson, J. J., Guzauskas, G. F., Chapman, R. H., Synnott, P. G., Liu, S., Russo, E. T., Pearson, S. D., Brouwer, E., & Ollendorf, D. A. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.1.29 · Cited by 52
“Total life years ranged from 3.25 for LEN+DEX to 6.97 for DAR+LEN+DEX.”
MethodInfluentialCermakova, K., & Hodges, H. C. (2018) · Molecules · doi:10.3390/molecules23081958 · Cited by 48
“It is also in Phase III trials for the treatment of acute myeloid leukemia and chronic lymphoblastic leukemia [133,134].”
BackgroundKlein, U., Kosely, F., Hillengaß, J., Hundemer, M., Schmitt, S., Neben, K., Moehler, T. M., Hegenbart, U., Ho, A. D., & Goldschmidt, H. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0561-1 · Cited by 51
“In two recently published phase III studies of lenalidomide/ dexamethasone combination therapy with no recommended anticoagulation, VTE occurred more often in the lenalidomide group compared to the placebo group with 14.7% vs. 3.4% (MM-009) and 11.4% vs. 4.6% (MM-010) [8, 11 ].”
BackgroundInfluentialKröger, N. M., Zabelina, T., Klyuchnikov, E., Kropff, M. H., Pflüger, K.-H., Burchert, A., Stübig, T., Wolschke, C., Ayuk, F., Hildebrandt, Y., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.142 · Cited by 50
Gay, F., Rajkumar, S. V., Coleman, M., Kumar, S. K., Mark, T. M., Dispenzieri, A. A., Pearse, R. N., Gertz, M. A., Leonard, J. P., Lacy, M. Q., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21777 · Cited by 50
“It has a different toxicity profile, with fewer nonhematologic side-effects compared with thalidomide and a more predictable and manageable toxicity [7,8].”
BackgroundCavo, M., Raimondo, F. D., Zamagni, E., Patriarca, F. F., Tacchetti, P., Casulli, A. F., Volpe, S., Perrone, G., Ledda, A., Ceccolini, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7389 · Cited by 55
Game of Bones: How Myeloma Manipulates Its Microenvironment
Moser-Katz, T., Joseph, N. S., Dhodapkar, M. V., Lee, K. P., & Boise, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.625199 · Cited by 53
Schmitz, S., Maguire, Á., Morris, J., Ruggeri, K., Haller, E., Kuhn, I., Leahy, J., Homer, N., Khan, A., Bowden, J., et al. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0509-7 · Cited by 48
Engelhardt, M. M., Kleber, M., Udi, J., Wäsch, R., Spencer, A. G., Patriarca, F. F., Knop, S. T., Bruno, B., Gramatzki, M., Morabito, F., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.487959 · Cited by 56
Self-citationHematologic malignancies and thrombosis
Elice, F., & Rodeghiero, F. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.11.034 · Cited by 49
“6% [37,38].”
Multiple myeloma with extramedullary disease
Oriol, A. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0079-0 · Cited by 49
Neri, P., Bahlis, N. J., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0184 · Cited by 48
“IMiDs, such as thalidomide, lenalidomide, and pomalidomide, exert significant activity in the treatment of multiple myeloma (2, 21, 22).”
BackgroundNew Agents in Multiple Myeloma: An Examination of Safety Profiles
Bringhen, S., de Wit, E., & Dimopoulos, M. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.05.003 · Cited by 55
Self-citationTumour and microparticle tissue factor expression and cancer thrombosis
Date, K. L., Hall, J., Greenman, J., Maraveyas, A., & Madden, L. A. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.11.013 · Cited by 56
Treatment of Relapsed/Refractory Multiple Myeloma
Kastritis, E., Palumbo, A., & Dimopoulos, M. A. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.01.004 · Cited by 55
“Lenalidomide oral cyclophosphamide dexamethasone Morgan et al112 21 62%/5% (nCR) 4 (1-8) 5.”
BackgroundSelf-citationHolkova, B., Zingone, A., Kmieciak, M., Bose, P., Badros, A. Z., Voorhees, P. M., Baz, R., Korde, N., Lin, H.-Y., Chen, J.-Q., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1076 · Cited by 48
New Insights into Therapeutic Targets in Myeloma
Anderson, K. C. (2011) · Hematology · doi:10.1182/asheducation-2011.1.184 · Cited by 52
Microenvironment and multiple myeloma spread
Ribatti, D., Moschetta, M., & Vacca, A. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50017-5 · Cited by 50
“A retrospective analysis of clinical trials, with previously treated relapsed/refractory MM, demonstrated an improved response rate and increased median for patients treated with lenalidomide and dexamethasone, compared to those treated only with dexamethasone [48-50].”
Liu, Y. M., Chen, X.-Q., Liang, H.-X., Zhang, F.-X., Zhang, B., Jin, J., Chen, Y., Cheng, Y.-X., & Zhou, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021930 · Cited by 49
“The use of high-dose chemotherapy followed by autologous stem cell transplantation as well as novel agents including thalidomide, bortezomib (BOR), and lenalidomide has increased remission rates and progression-free survival [4–7].”
BackgroundHou, J., Du, X., Jin, J., Cai, Z., Chen, F., Zhou, D.-B., Yu, L., Ke, X., Li, X., Wu, D., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-41 · Cited by 50
Case 23-2013: A 54-Year-Old Woman with Abdominal Pain, Vomiting, and Confusion
Kalantar-Zadeh, K., Uppot, R. N., & Lewandrowski, K. B. (2013) · New England Journal of Medicine · doi:10.1056/nejmcpc1208154 · Cited by 49
Saltarella, I., Morabito, F., Giuliani, N., Terragna, C., Omedè, P., Palumbo, A. P., Bringhen, S., Paoli, L. D., Martino, E. A., Larocca, A., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0691-4 · Cited by 48
Mechanisms of lenalidomide sensitivity and resistance
Martinez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 46
Bendamustine in patients with relapsed or refractory multiple myeloma
Michael, M., Bruns, I., Bölke, E., Zohren, F., Czibere, A. G., Safaian, N., Neumann, F., Haas, R. R., Kobbe, G., & Fenk, R. R. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-1-13 · Cited by 47
Weber, D. M., Graef, T. T., Hussein, M. A., Sobecks, R. M., Schiller, G. J., Lupinacci, L. C., Hardwick, J. S., & Jagannath, S. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.07.007 · Cited by 51
Lonial, S. (2010) · Hematology · doi:10.1182/asheducation-2010.1.303 · Cited by 52
Immunomodulatory drugs in multiple myeloma
Andhavarapu, S., & Roy, V. (2013) · Expert Review of Hematology · doi:10.1586/ehm.12.62 · Cited by 49
Richardson, P. G. G., Laubach, J. P., Schlossman, R. L., Mitsiades, C. S., & Anderson, K. C. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0115 · Cited by 48
Li, Y., YinHui, T., Yunliang, Z., & Sun, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16235 · Cited by 48
“The quality of the 11 studies was roughly evaluated in line with the Jadad scale: three studies had scores of 5 [7, 9, 11] four studies had scores of 4 [6, 10, 12, 13] and four studies had scores of 3 [2-4, 8] Score details for each study are shown in Table 1.”
BackgroundMethodInfluentialSzabó, Z., Foroughbakhshfasaei, M., Gál, R., Horváth, P., Komjáti, B., Noszál, B., & Tóth, G. (2017) · Journal of Separation Science · doi:10.1002/jssc.201701211 · Cited by 47
“It is currently approved for the treatment a number of hematological disorders, such as multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma [1, 2].”
BackgroundLeblay, N., Maity, R., Hasan, F., & Neri, P. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00636 · Cited by 53
Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.384 · Cited by 46
“All the patients were scheduled to undergo autologous SCT following standard high-dose melphalan (200 mg/m2).”
InfluentialBagratuni, T., Kastritis, E., Politou, M., Ρούσσου, Μ., Kostouros, E., Gavriatopoulou, M., Eleutherakis‐Papaiakovou, E., Kanellias, N., Terpos, E., & Dimopoulos, M. A. (2013) · American Journal of Hematology · doi:10.1002/ajh.23504 · Cited by 46
Self-citationCheikh, J. E., Crocchiolo, R., Fürst, S., Ladaique, P., Castagna, L., Faucher, C., Granata, A., Oudin, C., Lemarié, C., Calmels, B., et al. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.02.009 · Cited by 46
Managing treatment-related peripheral neuropathy in patients with multiple myeloma
Petrucci, M. T., Cesini, L., & Grammatico, S. (2016) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s91251 · Cited by 54
Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study
Torre, C. D., Zambello, R., Cacciavillani, M., Campagnolo, M., Berno, T., Salvalaggio, A., March, E. D., Barilà, G., Lico, A., Lucchetta, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003093 · Cited by 47
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions
Moreau, P., & de Wit, E. (2017) · British Journal of Haematology · doi:10.1111/bjh.14780 · Cited by 46
“Complete responses (CRs) or partial responses (PRs) were achieved in 61 0% of len/dex-treated patients in MM-009 and 60 2% in MM-010; the corresponding rates in the placebo/dex groups were 19 9% and 24 0%, respectively (P < 0 001 in both studies).”
MethodInfluentialIriyama, N., Hino, H., Moriya, S., Hiramoto, M., Hatta, Y., Takei, M., & Miyazawa, K. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1376741 · Cited by 46
“The use of various agents such as the proteasome inhibitor, bortezomib, and immunomodulatory drugs such as thalidomide and lenalidomide can dramatically improve the outcome of patients with MM, but these drugs cannot cure MM completely [1,2].”
BackgroundPathogenesis and treatment of multiple myeloma
Yang, P., Qu, Y., Wang, M., Chu, B., Chen, W., Zheng, Y., Niu, T., & Qian, Z. (2022) · MedComm · doi:10.1002/mco2.146 · Cited by 54
Burzynski, J. A., Toro, J. J., Patel, R. C., Lee, S., Greene, R. E., Ochoa-Bayona, J. L., Frei, C. R., & Freytes, C. O. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903085936 · Cited by 48
Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents.
Argyriou, A. A., Zolota, V., Kyriakopoulou, O., & Kalofonos, H. P. (2010) · PubMed · Cited by 51
Outcomes of primary refractory multiple myeloma and the impact of novel therapies
Majithia, N., Rajkumar, S. V., Lacy, M. Q., Buadi, F. K., Dispenzieri, A. A., Gertz, M. A., Hayman, S. R., Dingli, D., Kapoor, P., Hwa, Y. L., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24131 · Cited by 49
Sonneveld, P., de Wit, E., & Moreau, P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.007 · Cited by 46
“The incidence of PN is generally low and PN is less severe in atients receiving lenalidomide than in those receiving bortezomib Richardson et al., 2006; Dimopoulos et al., 2007; Weber et al., 007).”
BackgroundInfluentialNardone, B., Wu, S., Garden, B. C., West, D. P., Reich, L. M., & Lacouture, M. E. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.006 · Cited by 44
Dimopoulos, M. A., Swern, A. S., Li, J. S., Hussein, M. A., Weiss, L., Nagarwala, Y. M., & Baz, R. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.77 · Cited by 44
Self-citationBladé, J., Cibeira, M. T., de Larrea, C. F., & Rosiñol, L. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq363 · Cited by 56
Party, T. K. M. M. W., Kim, Y., Sohn, S., Lee, J.-H., Yang, D.-H., Moon, J., Ahn, J.-S., Kim, H., & Lee, J. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0856-x · Cited by 45
“However, the recent introduction of novel agents, such as bortezomib, thalidomide, and lenalidomide has resulted in clinically significant advances in the treatment of MM [9–12].”
BackgroundKorthals, M., Sehnke, N., Kronenwett, R., Schroeder, T. A., Strapatsas, T., Kobbe, G., Haas, R. R., & Fenk, R. R. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.04.025 · Cited by 46
“Treatment protocols using chemotherapy in combination with novel agents such as bortezomib [6] or lenalidomide [7,8] are continuously improving the depth of response.”
BackgroundTerpos, E., Christoulas, D., Kastritis, E., Katodritou, E., Παπαθεοδώρου, Α., Pouli, A. G., Kyrtsonis, M., Michalis, E., Papanikolaou, X., Gkotzamanidou, M. A., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23577 · Cited by 46
“Lenalidomide combined with dexamethasone (RD) is an effective treatment for patients with relapsed and/or refractory MM and provides an overall response (OR) rate of 60%, with a complete response (CR) rate of 15% [3,4].”
BackgroundSelf-citationScullen, T. A., Santo, L., Vallet, S., Fulciniti, M., Eda, H., Cirstea, D. D., Patel, K. J., Nemani, N., Yee, A. J., Mahindra, A. K., et al. (2013) · Leukemia · doi:10.1038/leu.2013.50 · Cited by 44
Iida, S., Chou, T., Okamoto, S., Nagai, H., Hatake, K., Murakami, H., Takagi, T., Shimizu, K., Lau, H. S. H., Takeshita, K., et al. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0624-7 · Cited by 44
“It has been reported that LD therapy was effective in patients with previous exposure to thalidomide or bortezomib [1, 2 , 10, 11].”
BackgroundMethodInfluentialThromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic review
Al‐Ani, F., Bastida, J. M., Mateos, M., & Louzada, M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.03.006 · Cited by 43
Bowcock, S. J., & Patrick, H. E. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07730.x · Cited by 43
Treatment of plasma cell dyscrasias with lenalidomide
Dimopoulos, M. A., Kastritis, E., & Rajkumar, S. V. (2008) · Leukemia · doi:10.1038/leu.2008.123 · Cited by 45
Self-citationNovel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment
Chanan-Khan, A. A., Miguel, J. F. S., Jagannath, S., Ludwig, H., & Dimopoulos, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0498 · Cited by 43
Self-citationSecond autologous transplant as salvage therapy in multiple myeloma
Atanackovic, D., & Schilling, G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12579 · Cited by 45
“Accordingly, the combination of lenalidomide and dexamethasone (len/dex) is capable of producing ORRs around 60%, a PFS around 11 months, and an OS of about 30 months in the relapsed setting (Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundRole of tumour angiogenesis in haematological malignancies
Medinger, M., & Passweg, J. R. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14050 · Cited by 43
Filho, R. J. P. D. M., Crusoé, E. D. Q., Riva, E., Bujan, W., Conte, G., Navarro-Cabrera, J. R., Garcia, D. K., Vega, G. E. Q., Macias, J., Alvear, J. W. O., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.005 · Cited by 42
Self-citationKunacheewa, C., & Orlowski, R. Z. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-112017-091045 · Cited by 43
Kulka, L. A. M., Fangmann, P.-V., Panfilova, D., & Olzscha, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00425 · Cited by 44
Venous thromboembolism in multiple myeloma: Current perspectives in pathogenesis
Uaprasert, N., Voorhees, P. M., Mackman, N., & Key, N. S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.007 · Cited by 42
Practical Management of Lenalidomide-Related Rash
Tinsley, S., Kurtin, S. E., & Ridgeway, J. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.008 · Cited by 41
de Montalembert, M., Ferster, A., Colombatti, R., Rees, D. C., Gulbis, B., & on behalf of the European Network for Rare and Congenital Anaemias (2010) · American Journal of Hematology · doi:10.1002/ajh.21865 · Cited by 42
Katodritou, E., Vadikolia, C., Lalagianni, C., Kotsopoulou, M., Papageorgiou, G., Kyrtsonis, M., Matsouka, P., Giannakoulas, N. C., Kyriakou, D. S., Karras, G., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1841-y · Cited by 41
“Our study confirms that RD is effective and safe in RRMM in the RW; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease.”
BackgroundResultInfluentialLenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
Palumbo, A. P., Larocca, A., Falco, P., Sanpaolo, G., Falcone, A. P., Federico, V., Canepa, L., Crugnola, M., Genuardi, M., Magarotto, V., et al. (2010) · Leukemia · doi:10.1038/leu.2010.58 · Cited by 41
Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Harousseau, J., & Dreyling, M. H. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp140 · Cited by 43
Self-citationComan, T., Bachy, E., Michallet, M., Socié, G., Uzunov, M., Bourhis, J. H., Lapusan, S., Brebion, A., Vigouroux, S., Maury, S., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.069328 · Cited by 41
“Time to relapse after allo-SCT (months) 11 (1-79)”
BackgroundThromboembolic Complications in Malignant Haematological Disorders
Castelli, R., Ferrari, B., Cortelezzi, A., & GUARIGLIA, A. (2010) · Current Vascular Pharmacology · doi:10.2174/157016110791330799 · Cited by 41
“The sedation, constipation and neuropathy associated with thalidomide are not commonly seen, but the risk of developing TEE during treatment with IMiD-containing combinations may be similar to that ascribed to thalidomide combinations [95].”
BackgroundDealing with Neuropathy in Plasma-Cell Dyscrasias
Sonneveld, P., & Jongen, J. L. M. (2010) · Hematology · doi:10.1182/asheducation-2010.1.423 · Cited by 44
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.